Everest Organics

Why is Everest Organics Ltd falling/rising?

As of 07-Aug, Everest Organics Ltd's stock price is at 299.40, down 2.52%, reflecting significant volatility and underperformance compared to the sector. Year-to-date, the stock has dropped 40.81%, with reduced investor participation contributing to the decline.

As of 07-Aug, Everest Organics Ltd's stock price is falling, currently at 299.40, which reflects a decrease of 7.75 or 2.52%. The stock has underperformed compared to the sector by 3.08% today. Although it opened with a gain of 3.86% and reached an intraday high of Rs 319, it also touched a low of Rs 297.05, indicating significant volatility within the trading day. <BR><BR>Moreover, the stock's performance over the past week shows a slight decline of 0.23%, while the benchmark Sensex has increased by 0.52%. Year-to-date, Everest Organics Ltd has seen a substantial drop of 40.81%, compared to a 7.89% decline in the Sensex. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 71.63% against the 5-day average. This decline in trading activity, combined with the stock's erratic trading pattern—having not traded on one day out of the last 20—contributes to the downward pressure on the stock price. <BR><BR>Overall, the combination of poor recent performance, reduced investor interest, and volatility in trading has led to the current decline in Everest Organics Ltd's stock price.

Which are the latest news on Everest Organics?

When is the next results date for Everest Organics Ltd?

The next results date for Everest Organics Ltd is 14 August 2026.

The next results date for Everest Organics Ltd is scheduled for 14 August 2026.

Should I buy, sell or hold Everest Organics Ltd?

How big is Everest Organics?

As of 10th June, Everest Organics Ltd has a market capitalization of 252.00 Cr, with net sales of 196.15 Cr and a net profit of 5.56 Cr over the latest four quarters. The company reported shareholder's funds of 69.95 Cr and total assets of 224.48 Cr for the annual period ending March 2025.

As of 10th June, Everest Organics Ltd has a market capitalization of 252.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Everest Organics reported Net Sales of 196.15 Cr and a Net Profit of 5.56 Cr.<BR><BR>For the latest annual period ending March 2025, the company had Shareholder's Funds of 69.95 Cr and Total Assets amounting to 224.48 Cr.

Who are in the management team of Everest Organics?

The management team of Everest Organics includes S K Hari Krishna (Whole-time Director), A Parvatisem (Director - Technical), K. Ramakrishnam Raju (Chairman & Independent Director), Raju S Kakarlapudi (Non-Executive Director), Srikakarlapudi Sirisha (Managing Director & CEO), Venkatasatyanarayana Murthy Chayaly (Independent Director), Abdur Rahman (Company Secretary & Compliance Officer), and SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPU (Independent Director). They oversee the company's operations and strategic direction.

The management team of Everest Organics includes the following individuals:<BR><BR>1. **S K Hari Krishna** - Whole-time Director<BR>2. **A Parvatisem** - Director (Technical)<BR>3. **K. Ramakrishnam Raju** - Chairman & Independent Director<BR>4. **Raju S Kakarlapudi** - Non-Executive Director<BR>5. **Srikakarlapudi Sirisha** - Managing Director & CEO<BR>6. **Venkatasatyanarayana Murthy Chayaly** - Independent Director<BR>7. **Abdur Rahman** - Company Secretary & Compliance Officer<BR>8. **SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPU** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Everest Organics?

Everest Organics' peers include Lyka Labs, Astonea Labs, Ambalal Sarabhai, Gennex Lab, BDH Industries, Kerala Ayurveda, Nectar Lifesci, Aarey Drugs, and Syschem (India). In terms of management risk and growth, Gennex Lab and BDH Industries perform best, while Everest Organics shows average management risk and below-average growth.

Peers: The peers of Everest Organics are Lyka Labs, Astonea Labs, Ambalal Sarabhai, Gennex Lab., BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, and Syschem (India).<BR><BR>Quality Snapshot: Excellent management risk is observed at Gennex Lab. and BDH Industries, while Average management risk is found at Lyka Labs, Astonea Labs, Everest Organics, and Nectar Lifesci. Below Average management risk is present at Ambalal Sarabhai, Kerala Ayurveda, Aarey Drugs, and Syschem (India). Growth is rated as Excellent at Gennex Lab. and BDH Industries, Good at Astonea Labs and Syschem (India), Average at Ambalal Sarabhai, and Below Average at Lyka Labs, Everest Organics, Kerala Ayurveda, Nectar Lifesci., and Aarey Drugs. Capital Structure is Excellent at Gennex Lab., Good at Syschem (India), Average at Ambalal Sarabhai, and Below Average at Lyka Labs, Astonea Labs, Everest Organics, Kerala Ayurveda, Nectar Lifesci., and Aarey Drugs.<BR><BR>Return Snapshot: Astonea Labs has the highest 1-year return at 58.56%, while Kerala Ayurveda has the lowest at -64.05%. Everest Organics' 1-year return of -39.86% is better than Kerala Ayurveda's but worse than Astonea Labs'. Additionally, the six-month returns for Kerala Ayurveda, Nectar Lifesci., and Everest Organics are negative.

What does Everest Organics do?

Everest Organics Ltd manufactures Active Pharmaceutical Ingredients and intermediaries in the Pharmaceuticals & Biotechnology sector. As of March 2026, it reported net sales of ₹49 Cr and a net profit of ₹3 Cr, with a market cap of ₹252 Cr.

Overview: <BR>Everest Organics Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediaries, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Everest Organics Limited was incorporated in February 1993 in Hyderabad. The company commenced its commercial operations in the same year and reported its latest quarterly results for March 2026, with net sales and profit figures available.<BR><BR>Financial Snapshot: <BR>- Net Sales: 49 Cr (Quarterly Results - Mar 2026) <BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2026) <BR>- Market Cap: INR 252 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 45.00 <BR>- Industry P/E: 34 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 0.65 <BR>- Return on Equity: 7.37% <BR>- Price to Book: 3.23 <BR><BR>Contact Details: <BR>Address: Aroor Village, Sadasivpet Mandal Medak Telangana : 502291 <BR>Tel: 91-8455-250113 <BR>Email: srihari_everest@rediffmail.com <BR>Website: http://www.everestorganicsltd.com

Are Everest Organics Ltd latest results good or bad?

Everest Organics Ltd's latest results are concerning, with a 68.97% decline in net profit and a 16.49% drop in revenue for Q3 FY26, leading to an 18.66% decrease in share price. These figures indicate significant operational challenges and unfavorable financial health.

The latest results for Everest Organics Ltd are concerning and can be classified as bad. The company reported a significant decline in both net profit and revenue for the third quarter of FY26. Specifically, net profit plummeted by 68.97% quarter-on-quarter to ₹0.36 crore, while revenue fell by 16.49% to ₹42.59 crore. This marks the steepest quarterly revenue drop in recent quarters and raises alarms about the company's operational efficiency and profitability.<BR><BR>Additionally, the operating margin contracted to 8.31%, down from 10.06% in the previous quarter, indicating rising cost pressures that the company has struggled to manage. The stock market reacted negatively to these results, with the share price dropping by 18.66% in a single day, reflecting investor concerns over the company's deteriorating financial health.<BR><BR>Overall, the combination of declining profitability, operational challenges, and a significant drop in stock price suggests that the latest results are indeed unfavorable for Everest Organics Ltd.

Is Everest Organics overvalued or undervalued?

As of December 4, 2025, Everest Organics is considered overvalued with a high PE ratio of 61.45 and other premium valuation metrics compared to its peers, indicating limited upside potential despite strong recent stock performance.

As of 4 December 2025, Everest Organics has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its high PE ratio of 61.45, an EV to EBIT of 41.56, and a Price to Book Value of 5.61. These ratios indicate that the stock is trading at a premium compared to its earnings and book value, suggesting limited upside potential relative to its current price.<BR><BR>In comparison to its peers, Everest Organics' valuation stands out as significantly higher; for instance, Sun Pharma has a PE of 37.78 and an EV to EBITDA of 24.99, while Cipla, which is rated attractive, has a PE of 22.58 and an EV to EBITDA of 15.98. This stark contrast highlights Everest Organics' overvaluation in the context of the industry. Despite its strong recent stock performance, with a year-to-date return of 39.15% compared to the Sensex's 9.12%, the underlying valuation metrics suggest that investors may be overestimating the company's growth prospects.

How has been the historical performance of Everest Organics?

Everest Organics has experienced a decline in financial performance, with net sales dropping from 197.24 Cr in March 2024 to 159.48 Cr in March 2025, resulting in negative profits and cash flow challenges. The company's operating profit decreased significantly, reflecting volatility and reduced profitability in the latest fiscal year.

Answer:<BR>The historical performance of Everest Organics shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Everest Organics reported net sales of 159.48 Cr in March 2025, a decline from 197.24 Cr in March 2024 and 183.05 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, falling to 159.48 Cr in March 2025 from 197.24 Cr in the previous year. Raw material costs decreased to 97.50 Cr in March 2025 from 123.41 Cr in March 2024, contributing to a total expenditure of 152.26 Cr, down from 186.25 Cr. Operating profit, excluding other income, was 7.22 Cr in March 2025, a decrease from 10.99 Cr in March 2024, leading to a profit before tax of -3.24 Cr in March 2025, compared to a profit of 0.61 Cr in March 2024. The profit after tax also turned negative at -1.29 Cr in March 2025, following a profit of 0.14 Cr in March 2024. The company's equity capital increased to 9.71 Cr in March 2025 from 8.00 Cr in March 2024, while total liabilities slightly decreased to 224.48 Cr from 226.62 Cr. Cash flow from operating activities was negative at -5.00 Cr in March 2025, contrasting with a positive cash flow of 16.00 Cr in March 2024, reflecting challenges in cash generation. Overall, the financial performance of Everest Organics indicates significant volatility and a decline in profitability in the most recent fiscal year.

Who are the top shareholders of the Everest Organics?

The top shareholders of Everest Organics include Veerat Finance Investment Limited with 38.37%, followed by Greenpath Energy Private Limited at 8.47%, and individual investors holding 23.87%. There are no pledged promoter holdings, mutual funds, or foreign institutional investors involved.

The top shareholders of Everest Organics include the promoters, with Veerat Finance Investment Limited holding the largest stake at 38.37%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Greenpath Energy Private Limited, which owns 8.47%. Additionally, individual investors collectively hold 23.87% of the shares.

What is the technical trend for Everest Organics?

As of April 3, 2025, Everest Organics shows a bullish trend supported by positive MACD and moving averages, but caution is advised due to bearish RSI readings indicating potential momentum weakness.

As of 3 April 2025, the technical trend for Everest Organics has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the RSI readings are bearish on both weekly and monthly time frames, suggesting some weakness in momentum. The Bollinger Bands are mildly bullish on both time frames, indicating potential for upward movement. Overall, the current stance is bullish, but the bearish RSI signals indicate caution regarding the strength of this trend.

Has Everest Organics declared dividend?

Everest Organics Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 15, 2022. Despite the dividend declaration, the yield remains at 0%, as the company's strong price returns have driven total returns across various periods.

Everest Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 15 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 190.1%, with a dividend return of 0%, resulting in a total return of 190.1%.<BR><BR>For the 1-year period, the price return was 249.94%, with a dividend return of 0%, leading to a total return of 249.94%.<BR><BR>Over the 2-year period, the price return was 325.04%, and the dividend return was 0%, culminating in a total return of 325.04%.<BR><BR>In the 3-year period, the price return was 182.86%, with a dividend return of 0.38%, resulting in a total return of 183.24%.<BR><BR>For the 4-year period, the price return was 15.24%, with a dividend return of 0.44%, leading to a total return of 15.68%.<BR><BR>In the 5-year period, the price return was 223.93%, with a dividend return of 1.72%, culminating in a total return of 225.65%.<BR><BR>Overall, while Everest Organics has declared a dividend, the dividend yield remains at 0%, indicating that the dividends have not significantly contributed to the total returns. However, the company has shown strong price returns across all periods, suggesting robust performance in its stock value.